Brandt JT - Search Results

1

Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease.

Braun OO, Johnell M, Varenhorst C, James S, Brandt JT, Jakubowski JA, Winters KJ, Wallentin L, Erlinge D, Siegbahn A. Braun OO, et al. Among authors: brandt jt. Thromb Haemost. 2008 Oct;100(4):626-33. Thromb Haemost. 2008. PMID: 18841285 Clinical Trial.

2

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.

Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, Naganuma H, Siegbahn A, Wallentin L. Jernberg T, et al. Among authors: brandt jt. Eur Heart J. 2006 May;27(10):1166-73. doi: 10.1093/eurheartj/ehi877. Epub 2006 Apr 18. Eur Heart J. 2006. PMID: 16621870 Clinical Trial.

3

A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.

Jakubowski JA, Payne CD, Li YG, Farid NA, Brandt JT, Small DS, Salazar DE, Winters KJ. Jakubowski JA, et al. Among authors: brandt jt. Thromb Haemost. 2008 Jan;99(1):215-22. doi: 10.1160/TH07-09-0555. Thromb Haemost. 2008. PMID: 18217157 Clinical Trial.

4

The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration.

Jakubowski JA, Payne CD, Li YG, Brandt JT, Small DS, Farid NA, Salazar DE, Winters KJ. Jakubowski JA, et al. Among authors: brandt jt. Thromb Haemost. 2008 Feb;99(2):409-15. doi: 10.1160/TH07-09-0575. Thromb Haemost. 2008. PMID: 18278193 Clinical Trial.

5

Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin.

Varenhorst C, James S, Erlinge D, Braun OO, Brandt JT, Winters KJ, Jakubowski JA, Olofsson S, Wallentin L, Siegbahn A. Varenhorst C, et al. Among authors: brandt jt. Am Heart J. 2009 Mar;157(3):562.e1-9. doi: 10.1016/j.ahj.2008.11.021. Epub 2009 Feb 6. Am Heart J. 2009. PMID: 19249429 Clinical Trial.

6

Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.

Varenhorst C, James S, Erlinge D, Brandt JT, Braun OO, Man M, Siegbahn A, Walker J, Wallentin L, Winters KJ, Close SL. Varenhorst C, et al. Among authors: brandt jt. Eur Heart J. 2009 Jul;30(14):1744-52. doi: 10.1093/eurheartj/ehp157. Epub 2009 May 9. Eur Heart J. 2009. PMID: 19429918 Free PMC article. Clinical Trial.

7

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.

Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS 2nd, Lachno DR, Salazar D, Winters KJ. Brandt JT, et al. J Thromb Haemost. 2007 Dec;5(12):2429-36. doi: 10.1111/j.1538-7836.2007.02775.x. Epub 2007 Sep 26. J Thromb Haemost. 2007. PMID: 17900275 Free article.

8

The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects.

Jakubowski JA, Payne CD, Brandt JT, Weerakkody GJ, Farid NA, Small DS, Naganuma H, Li GY, Winters KJ. Jakubowski JA, et al. Among authors: brandt jt. J Cardiovasc Pharmacol. 2006 Mar;47(3):377-84. doi: 10.1097/01.fjc.0000210069.47205.c0. J Cardiovasc Pharmacol. 2006. PMID: 16633079 Clinical Trial.

9

Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans.

Asai F, Jakubowski JA, Naganuma H, Brandt JT, Matsushima N, Hirota T, Freestone S, Winters KJ. Asai F, et al. Among authors: brandt jt. Platelets. 2006 Jun;17(4):209-17. doi: 10.1080/09537100600565551. Platelets. 2006. PMID: 16769598 Clinical Trial.

10

A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans.

Jakubowski JA, Matsushima N, Asai F, Naganuma H, Brandt JT, Hirota T, Freestone S, Winters KJ. Jakubowski JA, et al. Among authors: brandt jt. Br J Clin Pharmacol. 2007 Apr;63(4):421-30. doi: 10.1111/j.1365-2125.2006.02792.x. Epub 2006 Oct 31. Br J Clin Pharmacol. 2007. PMID: 17076696 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

118 results

Search Page